title: Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma.
abstract: OBJECTIVE
  Dysregulation of microRNA-100 (miR-100) has been reported to be involved in tumorigenesis and tumor progression of several cancer types. However, its expression patterns in tumors are controversial. The aim of this study was to investigate the expression and clinical significance of miR-100 in renal cell carcinoma (RCC).
  
  
  METHODS
  Real-time quantitative PCR was performed to detect the expression levels of miR-100 in 96 paired samples of RCC and adjacent non-cancerous renal tissues. Then, statistical analysis was performed to determine the associations of miR-100 expression with the clinical features and the prognosis of RCCs.
  
  
  RESULTS
  miR-100 expression was significantly higher in RCC tissues compared with adjacent non-cancerous renal tissues (5.3 ± 2.2 vs. 1.9 ± 0.8, P < 0.001). In addition, high miR-100 expression in RCC tissues was significantly associated with advanced tumor T stage (P = 0.005) and grade (P = 0.01), and the presence of metastasis (P = 0.008). Moreover, Kaplan-Meier analysis showed the significant differences in 5-year overall (50.0 vs. 83.3 %, P = 0.006) and tumor-specific survival (58.3 vs. 83.3 %, P = 0.008) for patients with high and low miR-100 expression, respectively. Furthermore, multivariable Cox regression analysis identified high miR-100 expression in RCC tissues as an independent poor prognostic marker of both overall (P = 0.01) and tumor-specific survival (P = 0.02) in patients with RCCs.
  
  
  CONCLUSIONS
  Our data offer convincing evidence that miR-100 overexpression strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with RCC. miR-100 expression may be a useful prognostic marker for this disease.
authors: Department of Nephrology, Huai'an First People's Hospital, Nanjing Medical University, 6 Beijing Road West, Huai'an 223300, Jiangsu, People's Republic of China.
authors: Guihua
authors: G
authors: Wang
authors: Lianhua
authors: L
authors: Chen
authors: Junsong
authors: J
authors: Meng
authors: Min
authors: M
authors: Chen
authors: Ling
authors: L
authors: Zhuang
authors: Liqin
authors: L
authors: Zhang
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000378:metabolism; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis
chemical_list: C544266:MIRN100 microRNA, human; D035683:MicroRNAs
references: Oncol Rep. 2012 Apr;27(4):1238-44
references: 22246341
references: Cancer Lett. 2012 Apr 28;317(2):184-91
references: 22120675
references: FEBS Lett. 2012 Jul 30;586(16):2375-81
references: 22684006
references: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
references: 14973191
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Urol Clin North Am. 2008 Nov;35(4):581-92; vi
references: 18992612
references: Oncogene. 2012 Jan 5;31(1):80-92
references: 21643017
references: Urol Oncol. 2007 Sep-Oct;25(5):387-92
references: 17826655
references: Genes Chromosomes Cancer. 2009 Jul;48(7):569-82
references: 19396866
references: Urol Oncol. 2013 Aug;31(6):796-801
references: 21880514
references: Clin Genitourin Cancer. 2012 Dec;10(4):262-70
references: 22959659
references: Urol Clin North Am. 2008 Nov;35(4):xiii-xvii
references: 18992606
references: Asian Pac J Cancer Prev. 2011;12(11):3001-4
references: 22393979
references: PLoS One. 2012;7(5):e35661
references: 22623952
references: Oncogene. 2013 Jul 4;32(27):3306-10
references: 22926517
references: BJU Int. 2000 Jul;86(1):20-7
references: 10886077
references: Urol Int. 2012;88(3):263-70
references: 22398398